Joseph McGowan, MD
Infectious Disease · Manhasset, NYNPI 1689654840
Payments from drug & device makers
What this record shows
That places this record below the midpoint for infectious disease clinicians in NY, where the typical reported total is $190.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
Across 226 payments — averaging $2779.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$336K
- Viiv Healthcare Company$131K
- AbbVie$122K
- GSK$35K
- Janssen Research & Development, LLC$5K
How this compares
$0 in reported general payments places this provider in the 15th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 721 | $2,823,536 |
| TivicayDolutegravir Sodium | 366 | $903,329 |
| RukobiaFostemsavir Tromethamine | 97 | $824,435 |
| DescovyEmtricitabine/Tenofov Alafenam | 300 | $678,223 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 129 | $646,075 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 132 | $552,267 |
| DovatoDolutegravir Sodium/Lamivudine | 84 | $249,696 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 44 | $207,474 |
| JulucaDolutegravir/Rilpivirine | 51 | $198,513 |
| SunlencaLenacapavir Sodium | 11 | $195,724 |
| PrezistaDarunavir | 88 | $178,014 |
| PifeltroDoravirine | 101 | $167,386 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 42 | $150,894 |
| PrezcobixDarunavir/Cobicistat | 62 | $141,446 |
| CabenuvaCabotegravir/Rilpivirine | 20 | $121,446 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Manhasset
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
- Stephen ThomasSyracuse$294K
- Glenn TurettFlushing$253K
- Genovefa PapanicolaouNew York$209K
- Abhay DhandValhalla$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.